Brevan Howard Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Brevan Howard Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-29,450	Closed	-$85.4K	–	1789
2025 Q3	$85.4K	Sell	29,450 -7,117	-19%	-$24.3K	﹤0.01%	1875
2025 Q2	$132K	Buy	+36,567	New	+$109K	﹤0.01%	1768
2024 Q4	–	Sell	-13,868	Closed	-$46.5K	–	1039
2024 Q3	$46.5K	Buy	+13,868	New	+$50.3K	﹤0.01%	1098
2024 Q2	–	Sell	-20,809	Closed	-$84.1K	–	1066
2024 Q1	$84.1K	Sell	20,809 -4,908	-19%	-$19.2K	﹤0.01%	909
2023 Q4	$78.4K	Buy	+25,717	New	+$77.9K	﹤0.01%	978

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brevan Howard Capital Management's AVIR Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 29,450 shares — an estimated $85.4K sold.

Brevan Howard Capital Management first reported a position in AVIR in Q4 2023 and held it in 5 quarters. The position peaked at $132K in Q2 2025. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

Brevan Howard Capital Management reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 29,450 Atea Pharmaceuticals shares in Q4 2025, an estimated $85.4K.
Brevan Howard Capital Management first reported a position in Atea Pharmaceuticals in Q4 2023 and held it in 5 quarters.
Brevan Howard Capital Management's Atea Pharmaceuticals position peaked at $132K in Q2 2025.
111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.